Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the safety, tolerability, and preliminary efficacy
of the monoclonal bispecific trifunctional antibody Catumaxomab in patients with non-muscle
invasive bladder cancer (NMIBC).